KalVista Pharmaceuticals (KALV) Competitors $11.13 +0.13 (+1.18%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$11.12 -0.01 (-0.09%) As of 10/24/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. SRPT, ETNB, MESO, OCUL, ANIP, VERA, COGT, STOK, VCEL, and RCUSShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Sarepta Therapeutics (SRPT), 89BIO (ETNB), Mesoblast (MESO), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Cogent Biosciences (COGT), Stoke Therapeutics (STOK), Vericel (VCEL), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Its Competitors Sarepta Therapeutics 89BIO Mesoblast Ocular Therapeutix ANI Pharmaceuticals Vera Therapeutics Cogent Biosciences Stoke Therapeutics Vericel Arcus Biosciences Sarepta Therapeutics (NASDAQ:SRPT) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability. Does the media prefer SRPT or KALV? In the previous week, Sarepta Therapeutics had 5 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 6 mentions for Sarepta Therapeutics and 1 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.91 beat Sarepta Therapeutics' score of 0.95 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Sarepta Therapeutics Positive KalVista Pharmaceuticals Very Positive Is SRPT or KALV more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.34%. Sarepta Therapeutics' return on equity of -1.03% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics-2.34% -1.03% -0.37% KalVista Pharmaceuticals N/A -212.79%-97.85% Which has preferable valuation & earnings, SRPT or KALV? Sarepta Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B1.17$235.24M-$0.87-26.22KalVista Pharmaceuticals$1.43M394.33-$183.44M-$3.94-2.82 Do analysts recommend SRPT or KALV? Sarepta Therapeutics currently has a consensus price target of $34.46, suggesting a potential upside of 51.07%. KalVista Pharmaceuticals has a consensus price target of $26.43, suggesting a potential upside of 137.45%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe KalVista Pharmaceuticals is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 7 Sell rating(s) 14 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.03KalVista Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more volatility and risk, SRPT or KALV? Sarepta Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500. Do institutionals and insiders hold more shares of SRPT or KALV? 86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.6% of Sarepta Therapeutics shares are held by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummarySarepta Therapeutics beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$555.75M$3.02B$6.24B$10.67BDividend YieldN/A57.75%5.72%4.81%P/E Ratio-2.8227.5331.1930.71Price / Sales394.33613.11560.36173.93Price / CashN/A168.3237.0861.44Price / Book5.805.6512.056.61Net Income-$183.44M$33.06M$3.33B$277.10M7 Day Performance0.27%3.16%1.93%2.56%1 Month Performance-8.02%8.14%7.77%3.77%1 Year Performance-4.71%-2.49%56.40%33.01% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.8117 of 5 stars$11.13+1.2%$26.43+137.5%-7.8%$555.75M$1.43M-2.82100Analyst ForecastSRPTSarepta Therapeutics4.544 of 5 stars$23.05+2.4%$34.42+49.3%-82.7%$2.20B$1.90B-26.491,372Analyst ForecastETNB89BIO2.8671 of 5 stars$14.80+0.3%$25.81+74.4%+90.3%$2.19BN/A-4.1040News CoverageAnalyst ForecastShort Interest ↓MESOMesoblast1.9725 of 5 stars$17.65+3.4%$24.00+36.0%+93.9%$2.18B$17.20M0.0080Analyst ForecastOCULOcular Therapeutix4.3202 of 5 stars$12.18+2.9%$22.63+85.8%+5.5%$2.06B$63.72M-9.52230Positive NewsAnalyst ForecastANIPANI Pharmaceuticals3.8842 of 5 stars$95.12+0.3%$99.14+4.2%+59.0%$2.06B$614.38M-123.53600News CoveragePositive NewsAnalyst UpgradeVERAVera Therapeutics2.7128 of 5 stars$30.20-3.3%$61.50+103.6%-26.6%$1.99BN/A-8.4440News CoverageAnalyst ForecastCOGTCogent Biosciences2.3071 of 5 stars$16.22-1.0%$19.67+21.2%+26.0%$1.87BN/A-9.1180News CoverageAnalyst ForecastSTOKStoke Therapeutics3.2784 of 5 stars$34.65+3.3%$30.83-11.0%+167.9%$1.84B$36.56M40.77100Analyst ForecastGap UpVCELVericel3.4507 of 5 stars$36.02+2.0%$58.40+62.1%-15.3%$1.78B$237.22M300.19300Analyst ForecastRCUSArcus Biosciences2.7733 of 5 stars$17.47+6.1%$27.22+55.8%-2.9%$1.75B$258M-5.51500Analyst ForecastGap Up Related Companies and Tools Related Companies SRPT Alternatives ETNB Alternatives MESO Alternatives OCUL Alternatives ANIP Alternatives VERA Alternatives COGT Alternatives STOK Alternatives VCEL Alternatives RCUS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts